U.S. markets closed

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
117.27+0.29 (+0.25%)
Al cierre: 04:00PM EST
117.76 +0.49 (+0.42%)
Fuera de horario: 05:29PM EST

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700

Empleados a tiempo completo3,045

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Jean-Jacques Bienaime M.B.A., MBAChairman & CEO3.67M8.16M1953
Mr. Brian R. MuellerExec. VP of Fin. & CFO1.13M343.97k1974
Dr. C. Greg Guyer Ph.D.CTO and Exec. VP of Global Manufacturing & Technical Operations1.75MN/D1962
Mr. Jeffrey Robert AjerExec. VP & Chief Commercial Officer1.2MN/D1962
Dr. Henry J. Fuchs M.D., Ph.D.Pres of Worldwide R&D1.52MN/D1958
Ms. Erin BurkhartGroup VP & Chief Accounting OfficerN/DN/DN/D
Traci McCartyVP of Investor RelationsN/DN/DN/D
Mr. George Eric DavisExec. VP & Chief Legal OfficerN/DN/D1971
Mr. Philip Lo ScalzoSr. VP & Chief Compliance OfficerN/DN/DN/D
Ms. Humaira SerajuddinSr. VP & Chief Marketing OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.


BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Gestión corporativa

La calificación ISS Governance QuickScore de BioMarin Pharmaceutical Inc. a partir del 1 de enero de 2023 es 6. Las puntuaciones principales son Auditoría: 5; Junta: 4; Derechos del accionista: 5; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.